PROTAC BRD9-binding moiety 1

Target: This ligand targets bromodomain-containing protein 9 (BRD9) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for bromodomain-containing protein 9 (BRD9). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings bromodomain-containing protein 9 (BRD9) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• BRD9-Engaging PROTAC Design: This ligand can be used as the BRD9-binding moiety in PROTAC constructs to recruit the E3 ubiquitin ligase and drive ubiquitination of BRD9. Such designs enable systematic evaluation of degrader potency, selectivity across BET-family proteins, and degradation kinetics in cell-based assays.

• BET-Selective Degradation Studies: Incorporating the BRD9-binding moiety into PROTACs supports targeted degradation of BRD9 while probing functional dependence of chromatin-associated pathways. Researchers can compare degradation profiles against related bromodomain targets to map selectivity determinants and identify conditions that minimize off-target protein loss.

• Chromatin Reader Functional Probing: PROTACs built with this BRD9-binding module can be applied to dissect BRD9-dependent transcriptional programs. By correlating BRD9 degradation with downstream gene expression and chromatin occupancy readouts, experiments can distinguish degradation-driven phenotypes from reversible occupancy effects.

• Structure-Guided Optimization: The BRD9-binding moiety provides a starting point for structure-guided PROTAC optimization, including linker length and attachment-site tuning. Iterative synthesis and testing can improve ternary complex formation, enhance ubiquitin transfer efficiency, and refine degradation selectivity for BRD9 in relevant cellular contexts.

PROTAC BRD9-binding moiety 1 is a BRD9 bromodomain target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of PROTAC BRD9-binding moiety 1 is characterized by carboxylic acid or carboxylate handle; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The acid handle supports amide coupling with amino-PEG, alkyl-diamine, piperazine, or aminoalkyl E3-ligase ligands. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.